Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.3029
-0.0076 (-2.45%)
Nov 19, 2025, 3:19 PM EST - Market open
Adial Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Adial Pharmaceuticals stock has a target of 1.50, which predicts a 395.21% increase from the current stock price of 0.3.
Price Target: $1.50 (+395.21%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Adial Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $1.5 | Hold → Strong Buy | Upgrades | $1.5 | +395.21% | Sep 30, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +2,541.14% | Nov 14, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +49,421.29% | Jul 11, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 17, 2022 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $300 | Strong Buy | Initiates | $300 | +98,942.59% | Oct 13, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.66
from -2.72
EPS Next Year
-0.60
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.56 | -0.40 | |||
| Avg | -0.66 | -0.60 | |||
| Low | -0.85 | -0.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.